Artwork for podcast Pathfinders in Biopharma
Is This the Breakthrough Moment for Genetic Medicine?
Episode 613th April 2023 • Pathfinders in Biopharma • RBC Capital Markets
00:00:00 00:17:24

Share Episode


Genetic medicine is poised to unlock more value for patients and investors due to disruptive technologies like mRNA, siRNA and gene editing. With an estimated 27 genetic medicines already approved, RBC’s biotechnology analyst Luca Issi explains how these technologies could be used next, and why companies able to combine the right choice of intervention with strong execution may stand to benefit most.